Nang Kuang Pharmaceutical Co., Ltd. (1752.TW)
TWD 35.65
(3.78%)
TWD 35.65
(3.78%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 755.56 Million TWD | 8.73% |
| 2022 | 694.9 Million TWD | 16.89% |
| 2021 | 594.46 Million TWD | -0.38% |
| 2020 | 596.75 Million TWD | -4.11% |
| 2019 | 622.3 Million TWD | 24.58% |
| 2018 | 499.51 Million TWD | -3.26% |
| 2017 | 516.34 Million TWD | -10.31% |
| 2016 | 575.7 Million TWD | 4.8% |
| 2015 | 549.32 Million TWD | 34.14% |
| 2014 | 409.51 Million TWD | 38.11% |
| 2013 | 296.52 Million TWD | -9.6% |
| 2012 | 328.01 Million TWD | 30.53% |
| 2011 | 251.29 Million TWD | 23.45% |
| 2010 | 203.56 Million TWD | -14.22% |
| 2009 | 237.32 Million TWD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 171.47 Million TWD | -6.02% |
| 2024 Q2 | 152.54 Million TWD | -11.04% |
| 2023 Q4 | 182.46 Million TWD | 1.23% |
| 2023 Q3 | 180.24 Million TWD | -4.8% |
| 2023 FY | 755.56 Million TWD | 8.73% |
| 2023 Q1 | 203.53 Million TWD | -8.56% |
| 2023 Q2 | 189.33 Million TWD | -6.98% |
| 2022 Q1 | 120 Million TWD | -21.23% |
| 2022 FY | 694.9 Million TWD | 16.89% |
| 2022 Q4 | 222.58 Million TWD | 30.68% |
| 2022 Q3 | 170.32 Million TWD | -6.41% |
| 2022 Q2 | 181.99 Million TWD | 51.66% |
| 2021 Q4 | 152.34 Million TWD | 0.41% |
| 2021 Q1 | 140.4 Million TWD | -0.68% |
| 2021 Q2 | 150 Million TWD | 6.83% |
| 2021 FY | 594.46 Million TWD | -0.38% |
| 2021 Q3 | 151.71 Million TWD | 1.14% |
| 2020 Q3 | 136.11 Million TWD | -11.46% |
| 2020 Q2 | 153.72 Million TWD | -7.14% |
| 2020 Q4 | 141.36 Million TWD | 3.86% |
| 2020 Q1 | 165.54 Million TWD | -20.24% |
| 2020 FY | 596.75 Million TWD | -4.11% |
| 2019 Q4 | 207.56 Million TWD | 30.05% |
| 2019 Q2 | 140.4 Million TWD | 22.37% |
| 2019 Q1 | 114.73 Million TWD | 0.02% |
| 2019 FY | 622.3 Million TWD | 24.58% |
| 2019 Q3 | 159.6 Million TWD | 13.68% |
| 2018 FY | 499.51 Million TWD | -3.26% |
| 2018 Q4 | 114.71 Million TWD | 2.68% |
| 2018 Q3 | 111.71 Million TWD | -20.72% |
| 2018 Q2 | 140.91 Million TWD | 6.62% |
| 2018 Q1 | 132.17 Million TWD | -14.39% |
| 2017 FY | 516.34 Million TWD | -10.31% |
| 2017 Q4 | 154.39 Million TWD | 25.11% |
| 2017 Q3 | 123.4 Million TWD | 6.7% |
| 2017 Q1 | 122.88 Million TWD | 7.25% |
| 2017 Q2 | 115.66 Million TWD | -5.88% |
| 2016 FY | 575.7 Million TWD | 4.8% |
| 2016 Q4 | 114.58 Million TWD | -20.83% |
| 2016 Q3 | 144.72 Million TWD | -6.61% |
| 2016 Q2 | 154.97 Million TWD | -4.0% |
| 2016 Q1 | 161.42 Million TWD | 3.4% |
| 2015 Q2 | 135.11 Million TWD | 8.44% |
| 2015 Q3 | 133.51 Million TWD | -1.18% |
| 2015 Q4 | 156.11 Million TWD | 16.93% |
| 2015 FY | 549.32 Million TWD | 34.14% |
| 2015 Q1 | 124.59 Million TWD | -5.5% |
| 2014 Q3 | 121.45 Million TWD | 52.93% |
| 2014 Q1 | 76.79 Million TWD | -12.8% |
| 2014 FY | 409.51 Million TWD | 38.11% |
| 2014 Q4 | 131.83 Million TWD | 8.55% |
| 2014 Q2 | 79.42 Million TWD | 3.42% |
| 2013 Q2 | 75.92 Million TWD | 12.69% |
| 2013 Q4 | 88.07 Million TWD | 35.19% |
| 2013 FY | 296.52 Million TWD | -9.6% |
| 2013 Q1 | 67.37 Million TWD | -15.36% |
| 2013 Q3 | 65.14 Million TWD | -14.19% |
| 2012 Q1 | 83.86 Million TWD | 28.93% |
| 2012 Q2 | 83.46 Million TWD | -0.48% |
| 2012 FY | 328.01 Million TWD | 30.53% |
| 2012 Q3 | 81.58 Million TWD | -2.25% |
| 2012 Q4 | 79.6 Million TWD | -2.43% |
| 2011 Q2 | 50.48 Million TWD | -35.26% |
| 2011 Q1 | 77.99 Million TWD | 63.96% |
| 2011 Q4 | 65.04 Million TWD | 12.58% |
| 2011 Q3 | 57.77 Million TWD | 14.43% |
| 2011 FY | 251.29 Million TWD | 23.45% |
| 2010 Q3 | 53.67 Million TWD | -2.39% |
| 2010 Q2 | 54.98 Million TWD | 16.14% |
| 2010 Q1 | 47.34 Million TWD | 0.0% |
| 2010 Q4 | 47.56 Million TWD | -11.37% |
| 2010 FY | 203.56 Million TWD | -14.22% |
| 2009 FY | 237.32 Million TWD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Maxigen Biotech Inc. | 424.09 Million TWD | -78.159% |
| SciVision Biotech Inc. | 512.49 Million TWD | -47.429% |
| Bionime Corporation | 715.65 Million TWD | -5.577% |
| Pegavision Corporation | 3.57 Billion TWD | 78.843% |
| Visco Vision Inc. | 857.15 Million TWD | 11.852% |